All News
ACR20 - Day 2 Report
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Read Article
Some really great & informative abstracts in #ANCA #vasculitis poster session! Incl work on thyroid disease such as ab#1433. This study confirmed the association with AAV but also showed PR3-ANCA is assoc. w/ less risk for thyroid disease.
#ACR20 @RheumNow
https://t.co/bMB0o8Eylo
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Kronzer and @jeffsparks presenting on lifestyle and clinical risk factors for RA-ILD. Obesity, CRP >=10mg/L, poor function, and high education level appear to be risks. Also threshold pk/yr effect for smoking #ACR20 @rheumnow https://t.co/dM73lBLXVN
Richard Conway RichardPAConway ( View Tweet)
Don’t forget to look for microscopic colitis in spondyloarthritis. It’ll solve many of your unsolved questions. #ACR20 poster session @RheumNow https://t.co/M7JubMtZiB
Sole RetamozoSole ( View Tweet)
Thinking about Dr. Fauci's forecast for a vaccine to be deployed early 2021. If/when it is offered, would you receive it?
@RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Egan presents 18-month data on use of anti-IL5 therapy in 13 EGPA patients. 50% reduction in steroid dose with anti-IL5. BVAS and asthma control questionnaire improved. 12 of 13 continued anti-IL5. @rheumnow #ACR20 Abstr#1427 https://t.co/qVy7Nb3OoA
Richard Conway RichardPAConway ( View Tweet)
Scurvy! Corkscrew hairs. Good exam question and we may still see it in the chips & sofa crowd and other poor eating habits. Learn from sailors re eating limes=limey. So have a twist of lemon or lime in your gin &tonic. If I guessed wrong oh well! @RheumNow @CRASCRRheum #ACR20 https://t.co/c8UN3bpPHC
Janet Pope Janetbirdope ( View Tweet)
Dr Giorgiutti and @Lupusreference present on prevalence of AAV in relation to silica exposure from quarries. Prevalence of GPA 2 fold higher in region with quarries vs city. Spatial association between quarries and GPA but not MPA/RLV. @rheumnow #ACR20 Abstr#1426 https://t.co/xHnOWCdXWe
Richard Conway RichardPAConway ( View Tweet)
Mepolizumab (anti-IL5) shown to be clinically beneficial and well-tolerated in the long-term for patients with #EGPA, with a 50% reduction in #steroid dose in the study cohort.
Abs#1427 #ACR20 @RheumNow #Vasculitis
https://t.co/elr6VR7447
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Juge @Juge_P_A reports on prevalence of subclinical RA-ILD as identified by HRCT. At mean disease duration of 13 years 18.2% of patients had subclinical RA-ILD. @rheumnow #ACR20 Abstr#1199 https://t.co/VWKFxwFfIJ
Richard Conway RichardPAConway ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by @RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Dr Lee reports on risk of melanoma and NMSC risk in RA in cohort study using propensity score matching. No difference in risk between MTX and HCQ overall. Increase BCC in MTX (HR 1.32) but less SCC (HR 0.77) @rheumnow #ACR20 Abstr#1001 https://t.co/LDWgfGK9LS
Richard Conway RichardPAConway ( View Tweet)
5yr DESIR cohort data estimated incidence rate of uveitis at 1.3/100p-y; over five years, uveitis was associated w/ dactylitis, biologic and sacroiliac MRI inflammation. #ABS1304 #ACR20 @RheumNow https://t.co/qmXlY7PmBB
Dr. Rachel Tate uptoTate ( View Tweet)
Important thoughts- how do we actually use the biologics in practice for the rare diseases that do not have many FDA approved options? @RheumNow #ACR20 abstract 1429 https://t.co/SsYC1kF5uv
alexa meara lexmeara ( View Tweet)
Shifting Treatment Paradigms in Psoriatic Arthritis: Dr. Eric Ruderman (@JointMD)
Chicago-based Dr. Eric Ruderman discussed the shifting treatment paradigms in psoriatic arthritis by reviewing abstracts #0504 and #2026 at #ACR20.
https://t.co/jsLkgWG63v https://t.co/h3r2oapOij
Links:
Dr. John Cush RheumNow ( View Tweet)
Nintedanib in rheum ILD (RA/SSc/CTD)
I appreciate the volumes might not seem like much, but:
- in first 1y Rx 20% more are spared a FVC decline>10%
- biggest diff in UIP-like pattern
With the right patient selection, nintedanib does have its place!
#ACR20 ABST1048/1049 @RheumNow https://t.co/jGZdR84bBU
David Liew drdavidliew ( View Tweet)
Time-trends analysis of in-hospital mortality in #vasculitis in the US shows it to have significantly declined in this population from 1998 to 2014.
Abs#1423 #ACR20 @RheumNow
https://t.co/TTI4DJiCRk
Mrinalini Dey DrMiniDey ( View Tweet)
Corkscrew hairs and swollen knee - what's your diagnosis? TM01 #ACR20 @RheumNow https://t.co/jOkI94AKr6
Eric Dein ejdein1 ( View Tweet)
Please take the new telemedicine survey- how can we help our patients during these unique times! @RheumNow #ACR20 https://t.co/n2jFfh1N9N
alexa meara lexmeara ( View Tweet)
So much more work to be done- the traditional tools for estimating CVD in rheumatic patients are likely not accurate especially patients with SLE- abstract 1286 @RheumNow #acr20 https://t.co/L6Z1fsO2he
alexa meara lexmeara ( View Tweet)